Diagnosis of Periodontal Disease Using Genetic Marker in Saliva

Identification of Novel Periodontal Disease Biomarkers Using microRNA Expression in Saliva

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02069574

Enrollment

Registered

2014-02-24

Start date

2014-03-31

Completion date

2015-12-31

Last updated

2014-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis

Brief summary

The purpose of the present study is to identify the novel periodontal disease biomarkers using differentially expressed microRNA in the saliva. The severity of chronic periodontal diseases and the time of pre- and post-treatment are major classification criteria. The obtained data will secure the foundation for the development of a new non-invasive diagnostic methods for early diagnosis & prognosis prediction of periodontal disease.

Interventions

PROCEDUREnon-surgical periodontal therapy

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

A. Severe Periodontal Disease * Patients with chronic severe periodontitis * Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing A. Moderate Periodontal Disease * Patients with chronic moderate periodontitis * Primary treatment of periodontal scaling, subgingival curettage is required, and the general progress of the protocol agreed with the basic periodontal therapy patients. * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing C. Healthy Control * Healthy periodontal patients ( more than 20 permanent teeth are present , in all parts of deep periodontal pockets measuring 4mm or less, and height is 2mm or less clinical attachment person) * subjects agreed collecting saliva and gingival crevicular fluid and physicochemical tests and genetic testing

Exclusion criteria

* Received periodontal treatment within the last six months * recently taken antibiotics within 3 months if you need a prescription antibiotic prophylaxis * taking the drug can affect periodontal status for a long period of time * pregnant or breastfeeding * In case of oral inflammatory mucosal disease (Lichen planus, etc.) * A history of alcoholism or drug abuse if * other special systemic disease (high blood pressure) * ages under 18

Design outcomes

Primary

Measure	Time frame
Expression level of MicroRNAs using Microarray	Change from Baseline in expression level of MicroRNAs at 1,6,12 months

Secondary

Measure	Time frame	Description
Expression level of cytokines using multiple cytokine analysis	Change from Baseline in expression level of cytokines at 1,6,12 months	* Pro-inflammatory biomarker : interleukin(IL)-1a, IL-1b, IL-6, IL-8 * Matrix metalloproteinase(MMP) : MMP-8, MMP-9 * Anti-inflammatory biomarker: IL-10, inhibitor of MMP (TIMP)-1

Countries

South Korea

Contacts

Primary ContactSu-Hwan Kim, PhD.

shkimperio@amc.seoul.kr82-2-3010-5797

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026